利培酮强化抗抑郁剂治疗双相抑郁发作的疗效观察.

OBJECTIVE: To probe into the clinical efficacy and safety of risperidone in treatment of bipolar depression. METHODS: 120 cases with depressive episode of bipolar depression admitted into Luoyang Mental Health Center from Feb.2010 to Oct. 2013 were selected to be divided into two groups via the random number table, with 60 cases in each. The control group were given VPA and CIT, while the observation group additionally received oral RIS bases on the control group. After 6 weeks, hamilton's depression scale 17 (HAMD-17), clinical global impression volume scale (CGI-SI) were adopted to conduct the evaluation, and then the clinical efficacy between two group of patients with bipolar depression were compared. RESULTS: The efficiency of observation group was significantly higher than that of control group [81. 67% (49 /60) VS 61. 67% (37 /60) ], with statistically significant difference (P < 0. 05). There was statistically significant difference in HAMD-17 score between two groups in the treatment of last 4 weeks and 6 weeks (P < 0. 05). There was no difference in CGI-SI score between two groups after treatment (P > 0. 05). The observation group and control group were respectively12. 00% and 19. 00% in switching rate, and the difference in the changes of SAS score was not statistically significant (P > 0. 05). CONCLUSIONS: The combination of VPA + CIT and VPA + CIT + RIS for the treatment of patients with bipolar depression has a relatively high safety, and the treatment effect of RIS is quicker and better. [ABSTRACT FROM AUTHOR]

目的:探讨利培酮强化抗抑郁剂治疗双相抑郁发作的临床疗效和安全性。方法:选取洛阳市精神卫生中心2010年2月—2013年10月收治的120例抑郁发作的双相情感障碍患者,按随机数字表法分为2组各60例,对照组患者给予丙戊酸钠(valproate,VPA)、西酞普兰(citalopram,CIT)进行治疗,观察组患者在此基础上每晚口服利培酮(risperidone,RIS)进行强化,6周后采用汉密尔顿17项抑郁量表(hamilton's depression scale 17,HAMD-17)、临床疗效总评量表(clinical efficacy of overall rating scale.of illness severity,CGI-SI)进行评价,比较2组双相抑郁发作患者的临床疗效。结果:观察组患者的总有效率为81.67%(49/60),明显高于对照组的61.67%(37/60),2组的差异有统计学意义(P<0.05);2组患者治疗后4周、6周HAMD-17评分比较,差异有统计学意义(P<0.05);2组患者治疗后CGI-SI评分比较,差异无统计学意义(P>0.05)。观察组与对照组患者的转相率别为12.00%和19.00%,且锥体外系不良反应量表评分变化比较,差异无统计学意义(P>0.05)。结论:联合VPA+CIT和VPA+CIT+RIS对双相抑郁发作患者进行治疗,安全性高,其中RIS强化抗抑郁剂治疗起效更快。 [ABSTRACT FROM AUTHOR]